Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Lubomierski, Nikolaus
Plotz, Guido
Wormek, Marc
Engels, Knut
Kriener, Susanne
Trojan, Jorg
Jungling, Bernd
Zeuzem, Stefan
and
Raedle, Jochen
2005.
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors.
Cancer,
Vol. 104,
Issue. 5,
p.
952.
Sridhar, Srikala S.
Hedley, David
and
Siu, Lillian L.
2005.
Raf kinase as a target for anticancer therapeutics.
Molecular Cancer Therapeutics,
Vol. 4,
Issue. 4,
p.
677.
Wilhelm, Scott
Carter, Christopher
Lynch, Mark
Lowinger, Timothy
Dumas, Jacques
Smith, Roger A.
Schwartz, Brian
Simantov, Ronit
and
Kelley, Susan
2006.
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Nature Reviews Drug Discovery,
Vol. 5,
Issue. 10,
p.
835.
Strumberg, D.
Awada, A.
Hirte, H.
Clark, J.W.
Seeber, S.
Piccart, P.
Hofstra, E.
Voliotis, D.
Christensen, O.
Brueckner, A.
and
Schwartz, B.
2006.
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?.
European Journal of Cancer,
Vol. 42,
Issue. 4,
p.
548.
Leicht, Deborah T.
Balan, Vitaly
Kaplun, Alexander
Singh-Gupta, Vinita
Kaplun, Ludmila
Dobson, Melissa
and
Tzivion, Guri
2007.
Raf kinases: Function, regulation and role in human cancer.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research,
Vol. 1773,
Issue. 8,
p.
1196.
Steinbild, S
Mross, K
Frost, A
Morant, R
Gillessen, S
Dittrich, C
Strumberg, D
Hochhaus, A
Hanauske, A-R
Edler, L
Burkholder, I
and
Scheulen, M
2007.
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
British Journal of Cancer,
Vol. 97,
Issue. 11,
p.
1480.
Blackburn, Jessica S.
Rhodes, C. Harker
Coon, Charles I.
and
Brinckerhoff, Constance E.
2007.
RNA Interference Inhibition of Matrix Metalloproteinase-1 Prevents Melanoma Metastasis by Reducing Tumor Collagenase Activity and Angiogenesis.
Cancer Research,
Vol. 67,
Issue. 22,
p.
10849.
Kim, D
Rath, O
Kolch, W
and
Cho, K-H
2007.
A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK Pathways.
Oncogene,
Vol. 26,
Issue. 31,
p.
4571.
Mross, K.
Steinbild, S.
Baas, F.
Gmehling, D.
Radtke, M.
Voliotis, D.
Brendel, E.
Christensen, O.
and
Unger, C.
2007.
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
European Journal of Cancer,
Vol. 43,
Issue. 1,
p.
55.
Gorelik, Gabriela
Fang, Jing Yuan
Wu, Ailing
Sawalha, Amr H.
and
Richardson, Bruce
2007.
Impaired T Cell Protein Kinase Cδ Activation Decreases ERK Pathway Signaling in Idiopathic and Hydralazine-Induced Lupus.
The Journal of Immunology,
Vol. 179,
Issue. 8,
p.
5553.
Kunick, Conrad
and
Egert‐Schmidt, Anne‐Marie
2008.
Die kurze Geschichte der Proteinkinase‐Inhibitoren. Jung, kompetitiv, erfolgreich.
Pharmazie in unserer Zeit,
Vol. 37,
Issue. 5,
p.
360.
Madhunapantula, SubbaRao V.
Desai, Dhimant
Sharma, Arati
Huh, Sung Jin
Amin, Shantu
and
Robertson, Gavin P.
2008.
PBISe, a novel selenium-containing drug for the treatment of malignant melanoma.
Molecular Cancer Therapeutics,
Vol. 7,
Issue. 5,
p.
1297.
Wilhelm, Scott M.
Adnane, Lila
Newell, Philippa
Villanueva, Augusto
Llovet, Josep M.
and
Lynch, Mark
2008.
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
Molecular Cancer Therapeutics,
Vol. 7,
Issue. 10,
p.
3129.
Dal Lago, Lissandra
D'Hondt, Véronique
and
Awada, Ahmad
2008.
Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors.
The Oncologist,
Vol. 13,
Issue. 8,
p.
845.
Puxeddu, Efisio
Durante, Cosimo
Avenia, Nicola
Filetti, Sebastiano
and
Russo, Diego
2008.
Clinical implications of BRAF mutation in thyroid carcinoma.
Trends in Endocrinology & Metabolism,
Vol. 19,
Issue. 4,
p.
138.
Minami, Hironobu
Kawada, Kenji
Ebi, Hiromichi
Kitagawa, Koichi
Kim, Yon‐il
Araki, Kazuhiro
Mukai, Hirofumi
Tahara, Makoto
Nakajima, Hikaru
and
Nakajima, Keiko
2008.
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Cancer Science,
Vol. 99,
Issue. 7,
p.
1492.
Kinkade, Rebecca
Dasgupta, Piyali
Carie, Adam
Pernazza, Daniele
Carless, Melanie
Pillai, Smitha
Lawrence, Nicholas
Sebti, Said M.
and
Chellappan, Srikumar
2008.
A Small Molecule Disruptor of Rb/Raf-1 Interaction Inhibits Cell Proliferation, Angiogenesis, and Growth of Human Tumor Xenografts in Nude Mice.
Cancer Research,
Vol. 68,
Issue. 10,
p.
3810.
Voliotis, Dimitris
and
Dumas, J.
2008.
Tumor Angiogenesis.
p.
655.
Borlak, Jürgen
and
Jenke, Hans Stephan
2008.
Cross-talk between Aryl Hydrocarbon Receptor and Mitogen-Activated Protein Kinase Signaling Pathway in Liver Cancer through c-raf Transcriptional Regulation.
Molecular Cancer Research,
Vol. 6,
Issue. 8,
p.
1326.
Cheung, Mitchell
Sharma, Arati
Madhunapantula, SubbaRao V.
and
Robertson, Gavin P.
2008.
Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development.
Cancer Research,
Vol. 68,
Issue. 9,
p.
3429.